Enveric Biosciences, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Jul 25 · Aug 25 · Sep 25)
Total Assets
$5M
↑+65.3% +$2Mvs FY2024
Total Liabilities
$918K
↓-38.4% -$571Kvs FY2024
Equity
$4M
↑+162.3% +$3Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $5M | $3M |
| Current Assets | $5M | $3M |
| Cash | $0 | $0 |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $5M | $3M |
| Non-Current Assets | $159K | $348K |
| PPE | $159K | $306K |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $42K |
| Investments | $0 | $0 |
| Other Non-Current | $0 | $0 |
| Total Liab+Eq | $4M | $2M |
| Current Liab. | $918K | $1M |
| Accounts Payable | $581K | $522K |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $337K | $968K |
| Non-Current Liab. | $0 | $0 |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $0 | $0 |
| Equity | $4M | $2M |
| Retained Earnings | $115M | $106M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · ENVB · Comparing FY2025 vs FY2024